We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Should You Buy Kimball Electronics Stock After Lackluster Q4 Results?
Read MoreHide Full Article
Key Takeaways
KE reported a 1-cent Q4 adjusted loss as revenues fell 2.3% year over year.
Medical sales rose 1% in Q4 and are expected to top one-third of Kimball's fiscal 2027 revenues.
Kimball guides for 7-9% fiscal 2027 revenue growth, with organic revenues rising 3-5%.
Kimball Electronics, Inc. (KE - Free Report) ended fiscal 2026 on a soft note, with fourth-quarter earnings falling sharply year over year and missing expectations. Revenues also declined from the prior-year period, reflecting continued weakness in some of the company’s key end markets.
However, the headline numbers apparently fail to reflect the inherent growth potential. Improving cash flow, a healthier balance sheet, strong momentum in Medical and expectations for a return to organic growth in fiscal 2027 suggest that Kimball’s underlying business is moving in the right direction. Let us dig a little deeper into the underlying factors.
Q4 Performance Falls Short
Kimball reported an adjusted loss of 1 cent per share for the fiscal fourth quarter against earnings of 34 cents in the year-ago quarter. The bottom line missed the Zacks Consensus Estimate of earnings of 40 cents.
Quarterly revenues of $371.6 million declined 2.3% year over year. Automotive revenues fell 3%, while Industrial sales decreased 5%. Medical revenues, however, increased 1% and remained the strongest-performing end market. Adjusted operating income declined to $18.1 million from $19.6 million a year ago, while the adjusted operating margin contracted 30 basis points to 4.9%.
However, revenues increased 5% sequentially, with all three end markets improving from the fiscal third quarter. Management also noted that adjusted operating income exceeded its internal expectations. This suggests that operating trends may be stabilizing even though year-over-year comparisons remain challenging.
Price Performance
Kimball has declined 18.7% in the past year against the industry’s growth of 53.2%. It has lagged peers like KLA Corporation (KLAC - Free Report) and Garmin Ltd. (GRMN - Free Report) . While GRMN has gained 18%, KLAC soared 101.3% over this period.
One-Year KE Stock Price Performance
Image Source: Zacks Investment Research
Medical Market: KE’s Key Growth Driver
Kimball’s growing exposure to the Medical market remains one of the biggest positives in its investment story. Medical revenues totaled $412.8 million in fiscal 2026 and represented 29% of total sales, up from 27% in fiscal 2025. Management expects Medical to account for more than one-third of revenues in fiscal 2027.
The recently completed acquisition of Helvoet Polymer Technologies should accelerate this shift. Helvoet expands Kimball’s capabilities in precision molding and manufacturing for applications such as diagnostics, microfluidics and drug delivery. The business is expected to contribute approximately $60 million in fiscal 2027 revenues and be accretive to adjusted earnings. The acquisition also broadens Kimball’s medical manufacturing footprint across Europe and India while creating potential cross-selling opportunities with existing customers.
At the same time, the company continues to invest in its new medical manufacturing facility in Indianapolis. Initial production is expected toward the end of calendar 2026. These should strengthen Kimball’s positioning in the high-growth Medical market and reduce its dependence on Automotive over time.
Fiscal 2027 Outlook Points to Recovery
Management’s fiscal 2027 guidance provides another reason for optimism. Kimball expects revenues between $1.535 billion and $1.56 billion, implying growth of 7-9% from fiscal 2026. Organic revenues are projected to increase 3-5%.
Medical organic sales are expected to grow at a high-single-digit to low-double-digit rate, while Industrial revenues should increase roughly in line with overall organic growth. Automotive revenues, however, are expected to remain almost flat.
Nevertheless, the overall outlook indicates that Kimball could return to sustainable top-line growth after a difficult fiscal 2026.
Cash Flow and Balance Sheet Lend Support
Kimball’s improving financial position strengthens the bullish argument. Cash generated from operations totaled $42.4 million in the fiscal fourth quarter, marking the company’s 10th consecutive quarter of positive operating cash flow. Cash conversion days improved to 82, the best level in 17 quarters.
Kimball ended June with $88.9 million in cash, while debt declined to $116.6 million, its lowest level in more than four years. The Helvoet acquisition will increase leverage somewhat, but the significant balance sheet improvement in fiscal 2026 gave management more flexibility to fund strategic growth investments.
Is KE Stock Worth Buying?
Kimball entered fiscal 2027 with considerable momentum. Strong medical market revenue provides a secular growth avenue, while inorganic growth is likely to gain steam.
The upbeat fiscal outlook adds further visibility to the growth story. Investors seeking exposure to the rapidly expanding electronics ecosystem may consider betting on KE for long-term upside.
View the Zacks #1 Rank List
Image: Bigstock
Should You Buy Kimball Electronics Stock After Lackluster Q4 Results?
Key Takeaways
Kimball Electronics, Inc. (KE - Free Report) ended fiscal 2026 on a soft note, with fourth-quarter earnings falling sharply year over year and missing expectations. Revenues also declined from the prior-year period, reflecting continued weakness in some of the company’s key end markets.
However, the headline numbers apparently fail to reflect the inherent growth potential. Improving cash flow, a healthier balance sheet, strong momentum in Medical and expectations for a return to organic growth in fiscal 2027 suggest that Kimball’s underlying business is moving in the right direction. Let us dig a little deeper into the underlying factors.
Q4 Performance Falls Short
Kimball reported an adjusted loss of 1 cent per share for the fiscal fourth quarter against earnings of 34 cents in the year-ago quarter. The bottom line missed the Zacks Consensus Estimate of earnings of 40 cents.
Quarterly revenues of $371.6 million declined 2.3% year over year. Automotive revenues fell 3%, while Industrial sales decreased 5%. Medical revenues, however, increased 1% and remained the strongest-performing end market. Adjusted operating income declined to $18.1 million from $19.6 million a year ago, while the adjusted operating margin contracted 30 basis points to 4.9%.
However, revenues increased 5% sequentially, with all three end markets improving from the fiscal third quarter. Management also noted that adjusted operating income exceeded its internal expectations. This suggests that operating trends may be stabilizing even though year-over-year comparisons remain challenging.
Price Performance
Kimball has declined 18.7% in the past year against the industry’s growth of 53.2%. It has lagged peers like KLA Corporation (KLAC - Free Report) and Garmin Ltd. (GRMN - Free Report) . While GRMN has gained 18%, KLAC soared 101.3% over this period.
One-Year KE Stock Price Performance
Image Source: Zacks Investment Research
Medical Market: KE’s Key Growth Driver
Kimball’s growing exposure to the Medical market remains one of the biggest positives in its investment story. Medical revenues totaled $412.8 million in fiscal 2026 and represented 29% of total sales, up from 27% in fiscal 2025. Management expects Medical to account for more than one-third of revenues in fiscal 2027.
The recently completed acquisition of Helvoet Polymer Technologies should accelerate this shift. Helvoet expands Kimball’s capabilities in precision molding and manufacturing for applications such as diagnostics, microfluidics and drug delivery. The business is expected to contribute approximately $60 million in fiscal 2027 revenues and be accretive to adjusted earnings. The acquisition also broadens Kimball’s medical manufacturing footprint across Europe and India while creating potential cross-selling opportunities with existing customers.
At the same time, the company continues to invest in its new medical manufacturing facility in Indianapolis. Initial production is expected toward the end of calendar 2026. These should strengthen Kimball’s positioning in the high-growth Medical market and reduce its dependence on Automotive over time.
Fiscal 2027 Outlook Points to Recovery
Management’s fiscal 2027 guidance provides another reason for optimism. Kimball expects revenues between $1.535 billion and $1.56 billion, implying growth of 7-9% from fiscal 2026. Organic revenues are projected to increase 3-5%.
Medical organic sales are expected to grow at a high-single-digit to low-double-digit rate, while Industrial revenues should increase roughly in line with overall organic growth. Automotive revenues, however, are expected to remain almost flat.
Nevertheless, the overall outlook indicates that Kimball could return to sustainable top-line growth after a difficult fiscal 2026.
Cash Flow and Balance Sheet Lend Support
Kimball’s improving financial position strengthens the bullish argument. Cash generated from operations totaled $42.4 million in the fiscal fourth quarter, marking the company’s 10th consecutive quarter of positive operating cash flow. Cash conversion days improved to 82, the best level in 17 quarters.
Kimball ended June with $88.9 million in cash, while debt declined to $116.6 million, its lowest level in more than four years. The Helvoet acquisition will increase leverage somewhat, but the significant balance sheet improvement in fiscal 2026 gave management more flexibility to fund strategic growth investments.
Is KE Stock Worth Buying?
Kimball entered fiscal 2027 with considerable momentum. Strong medical market revenue provides a secular growth avenue, while inorganic growth is likely to gain steam.
The upbeat fiscal outlook adds further visibility to the growth story. Investors seeking exposure to the rapidly expanding electronics ecosystem may consider betting on KE for long-term upside.
KE currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.